Patisiran: 7 agencies, 2018–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “For the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.”, while PBAC (Australia) recorded not recommended for “Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)”.
Assessment has run over 5.4 years, from 18 Sep 2018 at AWMSG (Wales) to 11 Feb 2024 at NYE METODER (Norway).
PBAC (Australia) changed its position: recommended in 2023, not recommended by 2023.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 4 of 11 records date from 2023 or later.
Against its own class, patisiran is an outlier: 88% of its decisive outcomes were positive, where molecules sharing ATC class N07X average 56%.
3 of these 11 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess patisiran, on 18 Sep 2018; NYE METODER (Norway) did not open a file until 11 Feb 2024 — a wide spread of 5.4 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
3 of the 7 agencies here assessed patisiran more than once, PBAC (Australia) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for patisiran.
The full ledger for patisiran reads 7 recommended, 1 other, 1 not recommended and 1 deferred, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 11 Feb 2024 | Behandling av hereditær (arvelig) transthyretin amyloidose (hATTR amyloidose) hos voksne pasienter med polynevropati i s… | decision recorded | source |
| PBAC (Australia) | 2023 | Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) | Recommended | source |
| DMC (Denmark) | 18 Nov 2020 | Arvelig transthyretin-medieret amyloidose (hATTR) | Anbefalet | source |
| AIFA (Italy) | 30 Jan 2020 | ONPATTRO è indicato per il trattamento dell’amiloidosi ereditaria mediata dalla transtiretina (amiloidosi hATTR) in pazi… | fully innovative, since expired | source |
| HAS (France) | 8 Jan 2020 | Listing (Transparency Committee) | SMR substantial · ASMR III | source |
6 further decisions for patisiran, across 5 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- tafamidis — same ATC class N07X — Other nervous system
- vutrisiran — same ATC class N07X — Other nervous system
- pitolisant — same ATC class N07X — Other nervous system
- fampridine — same ATC class N07X — Other nervous system
- omaveloxolone — same ATC class N07X — Other nervous system
- tofersen — same ATC class N07X — Other nervous system
Coverage: 11 decisions for patisiran from 7 agencies, 2018 to 2024. Data to 7 Sep 2026. ATC class N07X — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.